TriNetX数据库中巩膜炎亚型和相关眼部并发症的发病率和患病率。

IF 4.2 1区医学 Q1 OPHTHALMOLOGY

American Journal of Ophthalmology Pub Date : 2025-05-28 DOI:10.1016/j.ajo.2025.05.028

Matthew D. Spangler , Rayna F. Marshall , Nila Kirupaharan , Karen R. Armbrust , Meghan K. Berkenstock

{"title":"TriNetX数据库中巩膜炎亚型和相关眼部并发症的发病率和患病率。","authors":"Matthew D. Spangler , Rayna F. Marshall , Nila Kirupaharan , Karen R. Armbrust , Meghan K. Berkenstock","doi":"10.1016/j.ajo.2025.05.028","DOIUrl":null,"url":null,"abstract":"<div><div>Objective: To analyze the demographics, systemic and ocular comorbidities, and the yearly and cumulative incidence and prevalence of scleritis in the TriNetX United States Collaborative Network database from 2014 to 2023.</div><div>Design: Retrospective cohort study.</div><div>Participants: Out of 109,154,791 patients in TriNetX, 41,435 were diagnosed with scleritis.</div><div>Methods: Data were collected and analyzed by scleritis subtype: anterior, posterior, scleritis with corneal involvement, and scleromalacia perforans. Data collected included demographics, concurrent use of immunosuppressants, presence of an associated systemic disease, and ocular complications.</div><div>Main Outcome Measures: Incidence and prevalence (yearly and cumulative) of scleritis and its subtypes. Incidence of scleritis stratified by age and low vision and blindness in the scleritis cohort were analyzed from 2014 to 2023.</div><div>Results: Of the 41,435 scleritis patients, the majority were Caucasian (56.6%) and female (62.5%) with a mean ± standard deviation age of 58 ± 18 years. The most commonly prescribed immunosuppressants were prednisone, methylprednisolone, and methotrexate (34.1%, 22.4%, and 8.7%). The most commonly associated systemic disease was rheumatoid arthritis (9.9%), and the most prevalent ocular complication was glaucoma (9.9%). The 10-year cumulative incidence and 10-year prevalence rates of scleritis were 6.8 cases per 100,000 person-years and 35.4 cases per 100,000 persons, respectively. The 10-year cumulative incidence of low vision and blindness in the cohort of scleritis was 1263.6 cases per 100,000 person-years.</div><div>Conclusions: Demographics and comorbidities of the TriNetX scleritis cohort were similar to scleritis cohorts in previous studies. However, the overall scleritis incidence rate was higher when compared to the previous literature, with varying yearly incidence and prevalence scleritis subtype rates. Further research is needed to assess for the increasing incidence of low vision over time.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"277 ","pages":"Pages 365-374"},"PeriodicalIF":4.2000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incidence and Prevalence of Scleritis Subtypes and Associated Ocular Complications in the TriNetX Database\",\"authors\":\"Matthew D. Spangler , Rayna F. Marshall , Nila Kirupaharan , Karen R. Armbrust , Meghan K. Berkenstock\",\"doi\":\"10.1016/j.ajo.2025.05.028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Objective: To analyze the demographics, systemic and ocular comorbidities, and the yearly and cumulative incidence and prevalence of scleritis in the TriNetX United States Collaborative Network database from 2014 to 2023.</div><div>Design: Retrospective cohort study.</div><div>Participants: Out of 109,154,791 patients in TriNetX, 41,435 were diagnosed with scleritis.</div><div>Methods: Data were collected and analyzed by scleritis subtype: anterior, posterior, scleritis with corneal involvement, and scleromalacia perforans. Data collected included demographics, concurrent use of immunosuppressants, presence of an associated systemic disease, and ocular complications.</div><div>Main Outcome Measures: Incidence and prevalence (yearly and cumulative) of scleritis and its subtypes. Incidence of scleritis stratified by age and low vision and blindness in the scleritis cohort were analyzed from 2014 to 2023.</div><div>Results: Of the 41,435 scleritis patients, the majority were Caucasian (56.6%) and female (62.5%) with a mean ± standard deviation age of 58 ± 18 years. The most commonly prescribed immunosuppressants were prednisone, methylprednisolone, and methotrexate (34.1%, 22.4%, and 8.7%). The most commonly associated systemic disease was rheumatoid arthritis (9.9%), and the most prevalent ocular complication was glaucoma (9.9%). The 10-year cumulative incidence and 10-year prevalence rates of scleritis were 6.8 cases per 100,000 person-years and 35.4 cases per 100,000 persons, respectively. The 10-year cumulative incidence of low vision and blindness in the cohort of scleritis was 1263.6 cases per 100,000 person-years.</div><div>Conclusions: Demographics and comorbidities of the TriNetX scleritis cohort were similar to scleritis cohorts in previous studies. However, the overall scleritis incidence rate was higher when compared to the previous literature, with varying yearly incidence and prevalence scleritis subtype rates. Further research is needed to assess for the increasing incidence of low vision over time.</div></div>\",\"PeriodicalId\":7568,\"journal\":{\"name\":\"American Journal of Ophthalmology\",\"volume\":\"277 \",\"pages\":\"Pages 365-374\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002939425002624\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002939425002624","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：分析TriNetX美国合作网络数据库2014-2023年的人口统计学、全身和眼部合并症、年度和累积巩膜炎发病率和患病率。设计：回顾性队列研究。参与者：在TriNetX的109,154,791名患者中，41,435名被诊断为巩膜炎。方法：收集资料并按巩膜炎亚型进行分析：前巩膜炎、后巩膜炎、累及角膜的巩膜炎和穿孔性巩膜软化。收集的数据包括人口统计学、同时使用免疫抑制剂、存在相关的全身性疾病和眼部并发症。主要结局指标：巩膜炎及其亚型的发病率和流行率（每年和累计）。对2014-2023年按年龄、低视力和失明分层的巩膜炎发病率进行分析。结果：41435例硬膜炎患者中，以白人（56.6%）和女性（62.5%）居多，平均±标准差年龄为58±18岁。最常用的免疫抑制剂是强的松、甲基强的松和甲氨蝶呤（34.1%、22.4%和8.7%）。最常见的系统性疾病是类风湿关节炎（9.9%），最常见的眼部并发症是青光眼（9.9%）。10年累积发病率和10年患病率分别为每10万人年6.8例和每10万人年35.4例。在巩膜炎队列中，低视力和失明的10年累积发病率为每10万人年1263.6例。结论：TriNetX巩膜炎队列的人口统计学和合并症与以往研究中的巩膜炎队列相似。然而，与之前的文献相比，总体巩膜炎发病率更高，每年的发病率和流行巩膜炎亚型率不同。随着时间的推移，低视力发生率的增加需要进一步的研究来评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Incidence and Prevalence of Scleritis Subtypes and Associated Ocular Complications in the TriNetX Database

Objective: To analyze the demographics, systemic and ocular comorbidities, and the yearly and cumulative incidence and prevalence of scleritis in the TriNetX United States Collaborative Network database from 2014 to 2023.

Design: Retrospective cohort study.

Participants: Out of 109,154,791 patients in TriNetX, 41,435 were diagnosed with scleritis.

Methods: Data were collected and analyzed by scleritis subtype: anterior, posterior, scleritis with corneal involvement, and scleromalacia perforans. Data collected included demographics, concurrent use of immunosuppressants, presence of an associated systemic disease, and ocular complications.

Main Outcome Measures: Incidence and prevalence (yearly and cumulative) of scleritis and its subtypes. Incidence of scleritis stratified by age and low vision and blindness in the scleritis cohort were analyzed from 2014 to 2023.

Results: Of the 41,435 scleritis patients, the majority were Caucasian (56.6%) and female (62.5%) with a mean ± standard deviation age of 58 ± 18 years. The most commonly prescribed immunosuppressants were prednisone, methylprednisolone, and methotrexate (34.1%, 22.4%, and 8.7%). The most commonly associated systemic disease was rheumatoid arthritis (9.9%), and the most prevalent ocular complication was glaucoma (9.9%). The 10-year cumulative incidence and 10-year prevalence rates of scleritis were 6.8 cases per 100,000 person-years and 35.4 cases per 100,000 persons, respectively. The 10-year cumulative incidence of low vision and blindness in the cohort of scleritis was 1263.6 cases per 100,000 person-years.

Conclusions: Demographics and comorbidities of the TriNetX scleritis cohort were similar to scleritis cohorts in previous studies. However, the overall scleritis incidence rate was higher when compared to the previous literature, with varying yearly incidence and prevalence scleritis subtype rates. Further research is needed to assess for the increasing incidence of low vision over time.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Ophthalmology 医学-眼科学

CiteScore

9.20

自引率

7.10%

发文量

406

审稿时长

36 days

期刊介绍： The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect. The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports. Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.